← Back to patent-cliff list
Camlipixant
Tier C — Watch / tradeCamlipixant
AstraZeneca
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：P2RX3
Indications (approved)：Cough, Irritable bowel syndrome, Pruritus, Atopic dermatitis
Regional status
US
Phase III
2022-10-25
EU
Phase III
2022-10-25
China
Phase III
2022-12-05
Japan
Phase III
2022-12-05
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Camlipixant?
Approved indications include: Cough, Irritable bowel syndrome, Pruritus, Atopic dermatitis.
When does the Camlipixant patent expire?
No public expiry year is available for Camlipixant yet; this page updates once verified.
How do I get a quote for Camlipixant intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-03